Skip to content

JELY PHARMA

Active Private limited companyfounded 2015active for 11 yearsRue du Jardinier 8, 1315 IncourtKBO/BCE: BE 0635.630.013

Lifetime

10 annual accounts with figures on one time axis
peak of €278,487 in 2021
€253,186▲ 8.2%
peak of €112,018 in 2022
€20,540▲ 34.3%
peak of €107,496 in 2018
€381▼ 99.0%
€469,303▼ 0.2%
peak of 1.9 FTE in 2024
1.6 FTE▼ 15.8%
Board1 name since 2015
1 director
Documentsfilings and deeds
01-04-2026121 days before the deadline
2025financial year
Result from €15,299 to €20,540Staff from 1.9 FTE to 1.6 FTEDividend €57,500Equity from €37,341 to €381Cash from €26,990 to €89,529

Key points

from the 2025 annual accounts

Equity

€381 from €107,496 in 2018

Equity fell by 100% in 7 years.

Debts

€469,303 100% of the balance sheet
Financial debts 47%Suppliers 13%Taxes and wages 4%Other 36%

Of this, €248,220 falls due within a year.

Position in the sector

€381

Less equity than 88% of companies in retail trade. The sector median is €559,827, over 2,460 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 1,374 companies had the same profile as JELY PHARMA has now. Each dot stands for 4 companies, two years later.

96.0%
were still trading
1.6%
stopped another way
2.2%
went bankrupt
  • Micro
  • 10 to 20 years old
  • solvency under 10%
  • a profit under 5% of the balance sheet

Another 0.2% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 1,374 companies, not a prediction for JELY PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 18-08-2015
  • 93 sharesdeed of 27-02-2019
  • 93 sharesdeed of 27-02-2019
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0635630013
Registered office moved to Incourt The registered office moved from Woluwe-Saint-Pierre, avenue des Grands Prix 114, boîte 18 to Glimes (1315 Incourt), Rue du Jardinier 8b · changes role from manager to director · Registered office in the articles: Glimes (1315 Incourt), Rue du Jardinier 8b · General meeting of 09-06-2021 · Gazette deed
Merger: JELY PHARMA takes over PHARMACIE JEHAES MEISER acts as permanent representative · holds 93 shares · holds 93 shares · General meeting of 30-01-2019 · Gazette deed
Merger proposal: JELY PHARMA takes over PHARMACIE JEHAES MEISER The company holds all the shares of PHARMACIE JEHAES MEISER · Gazette deed
All 19 events

Comparable companies

same main activity, similar in size and age
Company
JELY PHARMA Incourt €469,684 €253,186 0.1% 1.6
Walemapotheek Mechelen €491,415 €242,339 3.9% 1.4
Apotheek Dok Noord Ghent €422,450 €291,562 4.9% 1.9
PHARMACIE QUERTON Anderlecht €442,937 €218,236 21.0% 1.6
Apotheek De Voldere Wingene €532,095 €321,424 64.2% 1.5
PHARMACIE THIRY ANNE Court-Saint-Etienne €628,009 €320,346 27.9% 1.9
PHARMACIE D'HONY Esneux €610,129 €232,839 61.0% 1.6

These companies have the same main activity as JELY PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €422,000 and €628,000, founded between 2012 and 2015.

Official details

Source: KBO
Status
Active since 19-08-2015Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Establishment unit
2.245.046.7861030 Schaerbeek, since 19-08-2015
Financial year end
31 December
Peppol
Reachable since 16-04-2025
Company details

Annual accounts 2025

≈ €870,000estimated
€469,684▼ 7.5%
Employeeson 31-12-2025
2=
Filing
Filed on 01-04-2026, 121 days before the end of the filing period
Financials

Insights on JELY PHARMA

JELY PHARMA has existed since 2015. The present size dates from 2019. The gross margin rose that year from €73,066 to €225,185.

Solvency fell in 2025 from 7.4% to 0.1% because of the dividend.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about JELY PHARMA

What is the company number of JELY PHARMA?
The company number of JELY PHARMA is 0635.630.013. The VAT number is the same number with BE in front: BE 0635.630.013.
Where is JELY PHARMA based?
The registered office is at Rue du Jardinier 8, 1315 Incourt.Company details
What does JELY PHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of JELY PHARMA?
JELY PHARMA is a private limited company (BV).
When was JELY PHARMA founded?
JELY PHARMA was founded on 19-08-2015.
Is JELY PHARMA still active?
Yes, JELY PHARMA is an active enterprise in the KBO register.
How many employees does JELY PHARMA have?
JELY PHARMA had an average of 1.6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of JELY PHARMA?
The turnover in financial year 2025 is about €870,000. This figure is estimated from the gross margin of €253,186 and 42 comparable companies (NACE 477). It probably lies between €690,000 and €1.2m.
Is JELY PHARMA profitable?
In financial year 2025, JELY PHARMA made a profit of €20,540.
Where can I find the annual accounts of JELY PHARMA?
JELY PHARMA filed 10 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of JELY PHARMA due?
JELY PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.